Tag: Alzheimer’s Disease
AriBio gets exclusive marketing rights in China for Alzheimer’s candidate AR1001 in $770m deal
In a significant stride towards addressing early Alzheimer’s disease, AriBio Co., Ltd. (AriBio) has announced an exclusive agreement to market AR1001, a pioneering investigational drug, ... Read More
Eisai invests $15m in C₂N Diagnostics to advance Alzheimer’s disease diagnostics
In a significant move for the field of brain health diagnostics, C₂N Diagnostics, LLC, a pioneer in developing advanced diagnostic solutions for Alzheimer's disease, has ... Read More
Alpha Cognition advances Alzheimer’s treatment with new patent filing
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a pioneering biopharmaceutical company in the development of novel treatments for neurodegenerative diseases, has recently taken a significant ... Read More
Schroders Capital invests in Neurona Therapeutics to advance neural cell therapies
In a significant development for the life sciences sector, Schroders Capital Global Innovation Trust plc has announced a strategic investment of $1.6 million (£1.3 million) ... Read More
Biogen reprioritizes Alzheimer’s disease resources, discontinues ADUHELM development
Biogen Inc. (Nasdaq: BIIB), a leading pharmaceutical company, today announced a strategic reprioritization of its resources in Alzheimer’s disease (AD), a key therapeutic area expected ... Read More
Halozyme Therapeutics announces licensing deal with Acumen Pharmaceuticals for Alzheimer’s therapy advancement
Halozyme Therapeutics, Inc. has entered a pivotal global collaboration and non-exclusive licensing agreement with Acumen Pharmaceuticals. This partnership focuses on utilizing Halozyme's ENHANZE drug delivery ... Read More
Corium, Lotus Pharmaceutical seal deal for Alzheimer’s drug ADLARITY in Asia
Corium, a biopharmaceutical frontrunner in the neuroscience arena, and Lotus Pharmaceutical, a global pharmaceutical powerhouse, have declared a collaboration and license agreement. This pact centers ... Read More
Lilly’s donanemab shows encouraging results in Phase 3 Alzheimer’s trial
Eli Lilly and Company (Lilly) revealed complete results from its Phase 3 TRAILBLAZER-ALZ 2 study at the 2023 Alzheimer's Association International Conference (AAIC), indicating that ... Read More
Quanterix launches diagnostic test aiding early Alzheimer’s detection
Quanterix, a biomarker detection firm powering scientific research and breakthrough diagnostics, has introduced LucentAD, a new test designed to aid in the evaluation of patients ... Read More
Roche, Lilly team up to develop EAPP blood test for Alzheimer’s disease
Roche is teaming up with Eli Lilly and Company (Lilly) to support the development of its Elecsys Amyloid Plasma Panel (EAPP) blood test which has ... Read More